tPA (Tissue Plasminogen Activator) Contraindications for Ischemic Stroke
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۲۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Eligible—
- Absolute Contraindication—
- Relative Contraindication—
The tPA (Tissue Plasminogen Activator) Contraindications for Ischemic Stroke calculates quantifying neurological deficit severity, stroke volume, and reperfusion therapy eligibility. Key inputs include symptom onset time. Scores guide initiating intravenous thrombolysis, activating endovascular thrombectomy pathways, or secondary prevention protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Evaluates eligibility and contraindications for thrombolytic therapy with IV tPA in acute ischemic stroke patients. Reviews absolute and relative contraindications based on AHA/ASA guidelines.
Clinical Indication
The tPA (Tissue Plasminogen Activator) Contraindications for Ischemic Stroke is indicated for bedside clinical practice to support Evaluates eligibility and contraindications for thrombolytic therapy with IV tPA in acute ischemic stroke patients. Reviews absolute and relative contraindications based on AHA/ASA guidelines.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.
Limitations & Contraindications
Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis. Clinical exclusion: This tool evaluates contraindications for IV tPA (alteplase) in acute ischemic stroke.
Clinical Pearls & Action Plan
Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility. Guideline pearl: Blood pressure must be <185/110 mmHg before and during treatment.
Assessment of absolute and relative contraindications based on AHA/ASA guidelines
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| symptom_onset_time | string | Yes | Time since symptom onset |
| age | integer | Yes | Patient age in years(years) |
| ischemic_stroke_within_3_months | string | Yes | History of ischemic stroke within 3 months |
| severe_head_trauma_within_3_months | string | Yes | Severe head trauma within 3 months |
| intracranial_surgery_within_3_months | string | Yes | Intracranial/intraspinal surgery within 3 months |
| history_intracranial_hemorrhage | string | Yes | History of intracranial hemorrhage |
| subarachnoid_hemorrhage | string | Yes | Symptoms suggestive of subarachnoid hemorrhage |
| gi_malignancy_bleeding_21_days | string | Yes | GI malignancy or GI bleeding within 21 days |
| coagulopathy | string | Yes | Bleeding diathesis or coagulopathy |
| inr_greater_1_7 | string | Yes | INR >1.7 or PT >15 seconds |
| aptt_greater_40 | string | Yes | aPTT >40 seconds |
| platelet_count_less_100k | string | Yes | Platelet count <100,000/mm³ |
| tc_48h_lmwh | string | Yes | Treatment dose LMWH within 24 hours |
| thrombin_factor_xa_inhibitors | string | Yes | Current use of direct thrombin or factor Xa inhibitors |
| glucose_less_50 | string | Yes | Blood glucose <50 mg/dL |
| ct_ich | string | Yes | CT demonstrates intracranial hemorrhage |
| ct_hypodensity_one_third | string | Yes | CT shows multilobar infarction (hypodensity >1/3 cerebral hemisphere) |
| sbp_greater_185 | string | Yes | Systolic BP >185 mmHg |
| dbp_greater_110 | string | Yes | Diastolic BP >110 mmHg |
| infective_endocarditis | string | Yes | Active infective endocarditis |
| aortic_dissection | string | Yes | Known or suspected aortic arch dissection |
| neoplasm_increased_bleeding | string | Yes | Intracranial neoplasm with increased bleeding risk |
| minor_symptoms | string | No | Only minor and non-disabling stroke symptoms |
| symptoms_clearing | string | No | Symptoms clearing spontaneously |
| pregnancy | string | No | Pregnancy |
| seizure_at_onset | string | No | Seizure at onset with postictal neurological impairments |
| major_surgery_14_days | string | No | Major surgery or serious trauma within 14 days |
| gi_hemorrhage_21_days | string | No | Recent GI or urinary tract hemorrhage within 21 days |
| mi_within_3_months | string | No | Recent acute myocardial infarction within 3 months |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | Eligible | No contraindications identified |
| — | Absolute Contraindication | One or more absolute contraindications present |
| — | Relative Contraindication | One or more relative contraindications present |
Evidence-Based References (EBM)
- Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418.
- Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29.
- Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Mar;44(3):870-947.